Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

Benzinga Newsdesk www.benzinga.com Positive 66.6%

Neg 0% Neu 0% Pos 66.6%

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.

Comments

No comments yet. Be the first!